Leuven (BELGIUM) – October 9, 2012 – TiGenix (Euronext Brussels: TIG) announced
today the publication in the International Journal of Colorectal Disease of the Phase I/II
study of Cx601: Expanded allogeneic adipose-derived stems cells (eASCs) for the
treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase
I/II clinical trial.

The authors of the study state that the full analysis of efficacy data at week 24 showed
69.2% of the patients with a reduction in the number of draining fistulas, while 56.3% of the
patients achieved complete closure of the treated fistula, and 30% of the cases presented
complete closure of all existing fistula tracts. The study, which is published online ahead of
print, can be accessed here: http://www.springerlink.com/content/j6k615530320kr02/

“We are delighted with the publication in a reputed clinical journal of this study that confirms
the significant benefit of our lead development product Cx601 in a very challenging
indication for which current treatments are suboptimal,” said Eduardo Bravo, CEO of
TiGenix. “The publication of these results in a peer-reviewed journal is a validation of the
thoroughness of our development program and demonstrates the increasing prominence of
cell therapy as an accepted clinical strategy that has the potential to considerably improve
on existing treatments paradigms.”

Cx601 is an adipose-derived allogeneic stem cell therapy that is delivered locally in the
fistula through intra-lesional injection. Cx601 is currently being investigated in the ADMIRECD
Phase III study. ADMIRE-CD is a multicenter, randomized, double-blind, placebocontrolled
Phase III trial of Cx601 in approximately 278 Crohn’s disease patients suffering
from complex perianal fistulas. The main objectives of the study are to demonstrate safety
and superior efficacy over placebo in perianal fistulas in Crohn’s disease patients after
failure with their previous treatment, in most cases biologicals, and to confirm the strong
safety and efficacy results from the Phase II trial completed in 2011. The results from
ADMIRE-CD are expected in H2, 2014. Information on the ADMIRE-CD trial can be found
at www.clinicaltrials.gov.